Targeted chimeric antigen receptor modified t cells for treatment of il13ralpha2 positive malignancies
US-2023405119-A1 · Dec 21, 2023 · US
Administration of engineered T cells for treatment of cancers in the central nervous system
US12472233B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12472233-B2 |
| Application number | US-202017025723-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 18, 2020 |
| Priority date | Feb 5, 2016 |
| Publication date | Nov 18, 2025 |
| Grant date | Nov 18, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An improved method of treating cancers with engineered T cells is described.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating a glioma in a human patient comprising administering intraventricularly to the patient a composition comprising an effective amount of T cells expressing a chimeric antigen receptor that binds to IL13 receptor α2. 2 . The method of claim 1 wherein the T cells are autologous or allogenic T cells. 3 . The method of claim 1 , wherein the administration is to the left ventricle or the right ventricle. 4 . The method of claim 1 , wherein the composition comprises at least 1×10 6 T cells. 5 . The method of claim 1 , wherein the composition comprising T cells is administered at least two times. 6 . The method of claim 5 , wherein administrations differ in the total number of T cells administered. 7 . The method of claim 5 , wherein the administrations escalate in dose. 8 . The method of claim 5 , wherein the administrations de-escalate in dose. 9 . The method of claim 1 , wherein the glioma is a diffuse, infiltrating tumor. 10 . The method of claim 1 , wherein one or more tumor foci decrease in size by at least 25%. 11 . The method of claim 1 , wherein the method is performed after tumor resection. 12 . The method of claim 1 , further comprising intratumoral administration of a composition comprising T cells. 13 . The method of claim 1 , wherein the glioma is glioblastoma. 14 . The method of claim 1 , wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO: 3. 15 . The method of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 31-48. 16 . The method of claim 1 , wherein the chimeric antigen receptor comprises amino acids 23-540 of SEQ ID NO: 10.
Assignees
Inventors
Classifications
IL-13 to IL-16 · CPC title
Receptors; Cell surface antigens; Cell surface determinants · CPC title
- A61K9/0085Primary
Brain, e.g. brain implants; Spinal cord · CPC title
Receptors for interleukins [IL] · CPC title
Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12472233B2 cover?
- An improved method of treating cancers with engineered T cells is described.
- Who is the assignee on this patent?
- Hope City
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0085. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).